SCHEMBL296175

SCHEMBL296175

O=C(/C=C/c1ccn(S(=O)(=O)c2ccc(CNCc3ccncc3)cc2)c1)NO

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 17/20 0.66
HDAC6 Q9UBN7 8/20 0.66
HDAC8 Q9BY41 13/20 0.64
HDAC3 O15379 13/20 0.64
HDAC2 Q92769 12/20 0.50
HDAC10 Q969S8 5/20 0.49
HDAC11 Q96DB2 5/20 0.49
HDAC9 Q9UKV0 5/20 0.49
HDAC4 P56524 5/20 0.49
HDAC5 Q9UQL6 5/20 0.49
HDAC7 Q8WUI4 4/20 0.49
KDM4E B2RXH2 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
KDM1A O60341 1/20 0.43
ABL1 P00519 1/20 0.43
EGFR P00533 1/20 0.43
ERBB2 P04626 1/20 0.43
INSR P06213 1/20 0.43
PDGFRB P09619 1/20 0.43
NAMPT P43490 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL296350 1.00 HDAC1 (0.66) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL295755 0.89 HDAC1 (0.68) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL295754 0.89 HDAC1 (0.68) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL296173 0.89 HDAC1 (0.60) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL296174 0.89 HDAC1 (0.60) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL297055 0.85 HDAC1 (0.62) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL297054 0.85 HDAC1 (0.62) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL295846 0.84 HDAC1 (0.67) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL295845 0.84 HDAC1 (0.67) HDAC1HDAC6HDAC8HDAC3HDAC2
SCHEMBL28763316 0.82 HDAC1 (0.62) HDAC1HDAC6HDAC8HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8969401-B2 Sulfonylpyrroles 4SC AG (DE) 2015-03-03 US claimed
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 EP claimed
US-20130079347-A1 NOVEL SULFONYLPYRROLES ALTANA PHARMA AG (DE) 2013-03-28 US claimed
US-8399505-B2 Sulfonylpyrroles 4SC AG (DE) 2013-03-19 US claimed
CN-1926103-B Sulfonyl pyrroles as HDAC inhibitors 4SC AG 2012-12-19 CN claimed
US-7842820-B2 Sulfonylpyrroles 4SC AG (DE) 2010-11-30 US claimed
US-20100261761-A1 Novel Sulfonylpyrroles MAIER THOMAS 2010-10-14 US claimed
US-20070184979-A1 Novel sulfonylpyrroles ALTANA PHARMA AG (DE) 2007-08-09 US claimed
CN-1926103-A Sulfonyl pyrroles as HDAC inhibitors ALTANA PHARMA AG (DE) 2007-03-07 CN claimed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP claimed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO claimed
WO-2019043176-A2 HDAC INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY 4SC AG (DE) 2019-03-07 WO disclosed
US-8969401-B2 Sulfonylpyrroles 4SC AG (DE) 2015-03-03 US disclosed
EP-1725528-B1 SULPHONYLPYRROLES AS HDAC INHIBITORS 4SC AG (DE) 2013-05-29 EP disclosed
EP-1928826-B1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS 4SC AG (DE) 2013-04-24 EP disclosed
WO-2007039404-A1 NOVEL SULPHONYLPYRROLES AS INHIBITORS OF HDAC S NOVEL SULPHONYLPYRROLES NYCOMED GMBH (DE) 2007-04-12 WO disclosed
WO-2007039403-A1 SULPHONYLPYRROLE HYDROCHLORIDE SALTS AS HISTONE DEACETYLASES INHIBITORS NYCOMED GMBH (DE) 2007-04-12 WO disclosed
CN-1926103-A Sulfonyl pyrroles as HDAC inhibitors ALTANA PHARMA AG (DE) 2007-03-07 CN disclosed
EP-1725528-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS Altana Pharma AG (DE) 2006-11-29 EP disclosed
WO-2005087724-A2 SULPHONYLPYRROLES AS HDAC INHIBITORS ALTANA PHARMA AG (DE) 2005-09-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070184979-A1 Novel sulfonylpyrroles HDAC1, HDAC4, HDAC3 HDAC1 1/4885HDAC6 8/4885HDAC8 9/4885
US-20100261761-A1 Novel Sulfonylpyrroles HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 7/4885HDAC8 11/4885
US-20130079347-A1 NOVEL SULFONYLPYRROLES HDAC3, HDAC1, HDAC2 HDAC1 2/4885HDAC6 7/4885HDAC8 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.